http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2693460-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73e0d5808f34f512649e277bd216a344 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2015-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0b884943016c7754cd10c178fe4d1ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e095c14fdf1de2b02052be8620f2edab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dedf094d8ac263d1f435e625bc4d469d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b9fd6f58d38097f980ffbb44d977fda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2a13630b16c1233dc6b41416a6fa0cb |
| publicationDate | 2019-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2693460-C2 |
| titleOfInvention | N2-(2-phenyl)-pyrido[3,4-d]pyrimidine-2,8-diamine derivatives and use thereof as mps1 inhibitor |
| abstract | FIELD: chemistry; pharmaceutics.SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, wherein in formula IRis selected from group comprising 5-member heteroaryl, optionally containing one or more (C-C) alkyl substitutes; Ris selected from a group comprising (C-C) alkoxy group or (C-C) fluoroalkoxy group; and Rand Rare linked to each other such that together with the nitrogen atom to which they are attached form 4-, 5-, 6- or 7-member heterocyclic ring bonded by the nitrogen atom, where said ring is optionally condensed with additional 3-member carbocyclic ring, to form a bicyclic heterocyclic system, or optionally linked through a spiran carbon atom with additional 4-, 5- or 6-member carbocyclic or heterocyclic ring to form a spirobicyclic ring system; and where the heterocyclic ring, bicyclic ring system or spirobicyclic ring system optionally contains one or more substitutes independently selected from a group comprising halogen, trifluoromethyl, difluoromethyl, cyano group, (C-C) alkyl, NRR, OR, where Rand Rall independently selected from a group comprising H or (C-C) alkyl; where each "heteroaryl" can contain from 1 to 4 heteroatoms independently selected from O, N and S atoms; and where each "heterocyclyl" or "heterocyclic group" can contain 1 or 2 heteroatoms independently selected from O, N and S. Invention also relates to methods of producing said compounds and a pharmaceutical composition for treating a disease or pathological condition associated with kinase activity Mps1, based on said compounds..EFFECT: technical result is obtaining novel compounds and pharmaceutical compositions based thereon, which can be used in medicine for treating and/or preventing proliferative diseases, such as cancer.17 cl, 62 ex |
| priorityDate | 2014-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1776.